Parabilis Medicines, Inc. (PBLS)
38.53
-0.83
(-2.11%)
USD |
NASDAQ |
Aug 24, 16:00
38.53
0.00 (0.00%)
After-Hours: 20:00
Parabilis Medicines Enterprise Value : 3.789B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 3.789B |
| August 20, 2026 | 3.816B |
| August 19, 2026 | 4.031B |
| August 18, 2026 | 3.787B |
| August 17, 2026 | 3.524B |
| August 14, 2026 | 3.506B |
| August 13, 2026 | 3.333B |
| August 12, 2026 | 3.548B |
| August 11, 2026 | 3.432B |
| August 10, 2026 | 3.340B |
| August 07, 2026 | 3.248B |
| August 06, 2026 | 3.322B |
| August 05, 2026 | 3.238B |
| August 04, 2026 | 3.361B |
| August 03, 2026 | 3.122B |
| July 31, 2026 | 3.124B |
| July 30, 2026 | 2.914B |
| July 29, 2026 | 2.852B |
| July 28, 2026 | 2.875B |
| July 27, 2026 | 2.857B |
| July 24, 2026 | 2.791B |
| July 23, 2026 | 2.980B |
| July 22, 2026 | 2.732B |
| July 21, 2026 | 2.637B |
| July 20, 2026 | 2.300B |
| Date | Value |
|---|---|
| July 17, 2026 | 2.577B |
| July 16, 2026 | 2.516B |
| July 15, 2026 | 2.621B |
| July 14, 2026 | 2.774B |
| July 13, 2026 | 2.587B |
| July 10, 2026 | 2.703B |
| July 09, 2026 | 2.677B |
| July 08, 2026 | 2.735B |
| July 07, 2026 | 2.676B |
| July 06, 2026 | 2.534B |
| July 02, 2026 | 2.581B |
| July 01, 2026 | 2.356B |
| June 30, 2026 | 2.308B |
| June 29, 2026 | 3.987B |
| June 26, 2026 | 3.941B |
| June 25, 2026 | 3.653B |
| June 24, 2026 | 3.766B |
| June 23, 2026 | 3.789B |
| June 22, 2026 | 3.792B |
| June 18, 2026 | 3.593B |
| June 17, 2026 | 3.614B |
| June 16, 2026 | 3.680B |
| June 15, 2026 | 3.493B |
| June 12, 2026 | 3.759B |
| June 11, 2026 | 4.120B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Moderna, Inc. | 54.06B |
| Kailera Therapeutics, Inc. | 1.319B |
| Arrowhead Pharmaceuticals, Inc. | 12.07B |
| Oncolytics Biotech, Inc. | 101.41M |
| Sangamo Therapeutics, Inc. | 50.70M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -52.46M |
| Revenue (Quarterly) | 0.148M |
| Total Expenses (Quarterly) | 52.61M |
| EPS Diluted (Quarterly) | -0.5421 |
| Gross Profit Margin (Quarterly) | -300.7% |
| Profit Margin (Quarterly) | -35.45K% |
| Earnings Yield | -4.97% |
| Normalized Earnings Yield | -4.885 |